Literature DB >> 31622224

Immune-Inflammation in Atherosclerosis: A New Twist in an Old Tale.

Atefe Ghamar Talepoor1, Hamed Fouladseresht1, Shahdad Khosropanah2, Mehrnoosh Doroudchi1.   

Abstract

BACKGROUND AND
OBJECTIVE: Atherosclerosis, a chronic and progressive inflammatory disease, is triggered by the activation of endothelial cells followed by infiltration of innate and adaptive immune cells including monocytes and T cells in arterial walls. Major populations of T cells found in human atherosclerotic lesions are antigen-specific activated CD4+ effectors and/or memory T cells from Th1, Th17, Th2 and Treg subsets. In this review, we will discuss the significance of T cell orchestrated immune inflammation in the development and progression of atherosclerosis. DISCUSSION: Pathogen/oxidative stress/lipid induced primary endothelial wound cannot develop to a full-blown atherosclerotic lesion in the absence of chronically induced inflammation. While the primary inflammatory response might be viewed as a lone innate response, the persistence of such a profound response over time must be (and is) associated with diverse local and systemic T cell responses. The interplay between T cells and innate cells contributes to a phenomenon called immuneinflammation and has an impact on the progression and outcome of the lesion. In recent years immuneinflammation, an old term, has had a comeback in connecting the puzzle pieces of chronic inflammatory diseases.
CONCLUSION: Taking one-step back and looking from afar at the players of immune-inflammation may help us provide a broader perspective of these complicated interactions. This may lead to the identification of new drug targets and the development of new therapies as well as preventative measures. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Atherosclerosis; T cells; cytokines; immune-inflammation; innate cells; therapeutic targets.

Mesh:

Substances:

Year:  2020        PMID: 31622224     DOI: 10.2174/1871530319666191016095725

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  6 in total

1.  APE1 inhibits foam cell formation from macrophages via LOX1 suppression.

Authors:  Zhaohui Hu; Bo Hui; Xuwei Hou; Ruhui Liu; Sergiy Sukhanov; Xiaohong Liu
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

2.  NADPH Oxidase Gene Polymorphism is Associated with Mortality and Cardiovascular Events in 7-Year Follow-Up.

Authors:  Milena Racis; Wojciech Sobiczewski; Anna Stanisławska-Sachadyn; Marcin Wirtwein; Elżbieta Bluj; Michał Nedoszytko; Joanna Borzyszkowska; Janusz Limon; Andrzej Rynkiewicz; Marcin Gruchała
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

3.  Functional subsets of circulating follicular helper T cells in patients with atherosclerosis.

Authors:  Atefe Ghamar Talepoor; Shahdad Khosropanah; Mehrnoosh Doroudchi
Journal:  Physiol Rep       Date:  2020-11

4.  T cell co-stimulator inducible co-stimulatory (ICOS) exerts potential anti-atherosclerotic roles through downregulation of vascular smooth muscle phagocytosis and proliferation.

Authors:  Zhixiong Zhong; Qunji Zhang; Linkai Tan; Xuemin Guo; Caiyan Gan
Journal:  Ann Transl Med       Date:  2020-12

Review 5.  Emerging Role of Compartmentalized G Protein-Coupled Receptor Signaling in the Cardiovascular Field.

Authors:  Bianca Plouffe; Alex R B Thomsen; Roshanak Irannejad
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-24

Review 6.  Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19.

Authors:  Hamed Fouladseresht; Mehrnoosh Doroudchi; Najmeh Rokhtabnak; Hossein Abdolrahimzadehfard; Amir Roudgari; Golnar Sabetian; Shahram Paydar
Journal:  Cytokine Growth Factor Rev       Date:  2020-10-09       Impact factor: 7.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.